DBVT
$19.84
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France.
Recent News
European Equities Traded in the US as American Depositary Receipts Higher Monday
European equities traded in the US as American depositary receipts were rising on Monday morning, up
DBV Technologies Details VIASKIN Peanut BLA Timeline, Launch Plan at Citizens Life Sciences Conference
DBV Technologies (NASDAQ:DBVT) outlined its late-stage plans for VIASKIN Peanut and its broader epicutaneous immunotherapy platform during a presentation at the Citizens Life Sciences Conference, with CFO Virginie Boucinha and Chief Commercial Officer Kevin Trapp detailing regulatory timelines, clin
European Equities Traded in the US as American Depositary Receipts Edge Lower in Wednesday Trading
European equities traded in the US as American depositary receipts edged lower late Wednesday mornin
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading
European equities traded in the US as American depositary receipts late Tuesday morning, rising 1.12
European Equities Traded in the US as American Depositary Receipts Decline in Monday Trading
European equities traded in the US as American depositary receipts were tracking slightly lower late